We also identified three tumors with targetable RTK lesions (PDGFRA, ERBB2, ERBB4) that were exclusive to the recurrent tumor (HGG5, HG8, HGG11), indicating that genomic data from tumor tissue at recurrence may provide better guidance for therapeutic choices. Here, ERBB4 is linked to neoplasm.